Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
First Claim
Patent Images
1. A method of alleviating symptoms in a subject having, or suspected of having, Huntington'"'"'s disease (HD), comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), wherein the antibody or fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs:
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
14, 15, and 16, respectively.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
60 Citations
23 Claims
-
1. A method of alleviating symptoms in a subject having, or suspected of having, Huntington'"'"'s disease (HD), comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), wherein the antibody or fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs:
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
14, 15, and 16, respectively. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
-
14. A method of reducing astrocyte activation in a subject having, or suspected of having Huntington'"'"'s Disease, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to SEMA4D, wherein the antibody or fragment thereof modulates astrocyte-mediated maintenance of the integrity of the blood-brain barrier, and wherein the antibody or fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs:
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
14, 15, and 16, respectively. - View Dependent Claims (15, 16, 17, 18)
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
-
19. A method of maintaining or restoring astrocyte-mediated trophic support of oligodendrocyte precursor cells (OPCs) in a subject having, or suspected of having, Huntington'"'"'s disease (HD), comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to SEMA4D, wherein the antibody or fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs:
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
14, 15, and 16, respectively, and wherein the antibody or fragment thereof reduces retraction of astrocyte processes and chemotactic movement of OPCs toward regions of damage. - View Dependent Claims (20, 21, 22, 23)
- 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;
Specification